References

1. Kerner, J. Vergiftung durch verdorbene Wurste. Tübinger Blätter f. Naturwissensch. u Arzneykunde. 1817, 3, 1–25.Kerner, J. Vergiftung durch verdorbene Wurste. Tübinger Blätter Nat. Arzneykunde 1817, 3, 1–25.
2. Van Ermengem, E. Über eine neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. Z. Hyg. Infektionskrankh. 1897, 26, 1–56.Van Ermengem, E. Über eine neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. Z. Hyg. Infektionskrankh. 1897, 26, 1–56.
3. Scott, A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Opthalmol. 1980, 87, 1044–1049.Scott, A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Opthalmology 1980, 87, 1044–1049.
4. Jankovic, J.; Brin, M.F. Therapeutic uses of botulinum toxin. N. Engl. J. Med. 1991, 324, 1186–1194. [PubMed]Jankovic, J.; Brin, M.F. Therapeutic uses of botulinum toxin. N. Engl. J. Med. 1991, 324, 1186–1194.
5. Truong, D.D.; Stenner, A.; Reichel, G. Current clinical applications of botulinum toxin. Curr. Pharm. Des. 2009, 15, 3671–3680. [CrossRef] [PubMed]Truong, D.D.; Stenner, A.; Reichel, G. Current clinical applications of botulinum toxin. Curr. Pharm. Des. 2009, 15, 3671–3680.
6. Hallett, M.; Albanese, A.; Dressler, D.; Segal, K.R.; Simpson, D.M.; Truong, D.; Jankovic, J. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 2013, 67, 94–114. [CrossRef] [PubMed]Hallett, M.; Albanese, A.; Dressler, D.; Segal, K.R.; Simpson, D.M.; Truong, D.; Jankovic, J. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 2013, 67, 94–114.
7. Persaud, R.; Garas, G.; Silva, S.; Stamatoglou, C.; Chatrath, P.; Patel, K. An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. JRSM Short. Rep. 2013, 4, 10. doi: 10.1177/2042533312472115Persaud, R.; Garas, G.; Silva, S.; Stamatoglou, C.; Chatrath, P.; Patel, K. An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. JRSM Short Rep. 2013, 4, 1–9.
8. Jankovic, J. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon 2018, 147, 84–88. doi: 10.1016/j.toxicon.2017.09.003 [CrossRef] [PubMed]Jankovic, J. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon 2018, 147, 84–88.
9. Anandan, C.; Jankovic, J. Botulinum toxin in movement disorders: An update. Toxins 2021, 13, 42.doi: 10.3390/toxins13010042Anandan, C.; Jankovic, J. Botulinum toxin in movement disorders: An update. Toxins 2021, 13, 42.
10. Jankovic, J.; Orman, J. Botulinum a toxin for cranial-cervical dystonia: A double-blind, placebo-controlled study. Neurology 1987, 37, 616–623. [CrossRef] [PubMed]Jankovic, J.; Orman, J. Botulinum a toxin for cranial-cervical dystonia: A double-blind, placebo-controlled study. Neurology 1987, 37, 616–623.
11. Blitzer, A.; Brin, M.; Greene, P.E.; Fahn, S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann. Otol. Rhinol. Laryngol. 1989, 98, 93–97. [CrossRef] [PubMed]Blitzer, A.; Brin, M.; Greene, P.E.; Fahn, S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann. Otol. Rhinol. Laryngol. 1989, 98, 93–97.
12. Jankovic, J.; Schwartz, K.; Donovan, D.T. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J. Neurol. Neurosurg. Psychiatry 1990, 53, 633–639. [CrossRef] [PubMed]Jankovic, J.; Schwartz, K.; Donovan, D.T. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J. Neurol. Neurosurg. Psychiatry 1990, 53, 633–639.
13. Hermanowicz, N.; Truong, D.D. Treatment of oromandibular dystonia with botulinum toxin. Laryngoscope 1991, 101, 1216–1218. doi: 10.1288/00005537-199111000-00010Hermanowicz, N.; Truong, D.D. Treatment of oromandibular dystonia with botulinum toxin. Laryngoscope 1991, 101, 1216–1218.
14. Tan, E.K.; Jankovic, J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 1999, 53, 2102–2107. [CrossRef] [PubMed]Tan, E.K.; Jankovic, J. Botulinum toxin A in patients with oromandibular dystonia: Long-term follow-up. Neurology 1999, 53, 2102–2107.
15. Yoshida, K.; Iizuka, T. Botulinum toxin treatment for upper airway collapse resulting from temporomandibular joint dislocation due to jaw-opening dystonia. Cranio 2006, 24: 217–222. doi: 10.1179/crn.2006.035.Yoshida, K.; Iizuka, T. Botulinum toxin treatment for upper airway collapse resulting from temporomandibular joint dislocation due to jaw-opening dystonia. Cranio 2006, 24, 217–222.
16. Bakke, M.; Larsen, B.M.; Dalager, T.; Møller, E. Oromandibular dystonia–functional and clinical characteristics: a report on 21 cases. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2013, 115, e21–e26. doi: 10.1016/j.oooo.2012.04.023Bakke, M.; Larsen, B.M.; Dalager, T.; Møller, E. Oromandibular dystonia–functional and clinical characteristics: A report on 21 cases. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2013, 115, e21–e26.
17. Sinclair, C.F.; Gurey, L.E.; Blitzer, A. Oromandibular dystonia: Long-term management with botulinum toxin. Laryngoscope 2013, 123, 3078–3083. [CrossRef] [PubMed]Sinclair, C.F.; Gurey, L.E.; Blitzer, A. Oromandibular dystonia: Long-term management with botulinum toxin. Laryngoscope 2013, 123, 3078–3083.
18. Albanese, A.; Bhatia, K.; Bressman, S.B.; Delong, M.R.; Fahn, S.; Fung, V.S.; Hallett, M.; Jankovic, J.; Jinnah, H.A.; Klein, C.; et al. Phenomenology and classification of dystonia: A consensus up date. Mov. Disord. 2013, 28, 863–873. doi: 10.1002/mds.25475.Yoshida, K. Computer-aided design/computer-assisted manufacture-derived needle guide for injection of botulinum toxin into the lateral pterygoid muscle in patients with oromandibular dystonia. J. Oral Facial Pain Headache 2018, 32, e13–e21.
19. Oppenheim, H. Über eine eigenartige Krampfkrankheit des kindlichen und jugendlichen Alters (Dysbasia lordotica progressiva, Dystonia musculorum deformans). Neurologie Centralblatt 1911, 30, 1090–1107.Scorr, L.M.; Silver, M.R.; Hanfelt, J.; Sperin, E.; Freeman, A.; Jinnah, H.A.; Factor, S.A. Pilot single-blind trial of AbobotulinumtoxinA in oromandibular dystonia. Neurotherapeutics 2018, 15, 452–458.
20. Romberg, M.H. Krampf im Muskelgebiete der Pars minor Quinti. Masticatorischer Gesichtskrampf. Trismus. In: Lehrbuch der Nervenkrankheiten des Menschen, Alexander Duncker, Berlin, 1846; pp. 308–316.Skármeta, N.P.; Espinoza-Mellado, P.; Chana, P. Orofacial dystonia and other oromandibular movement disorders. In Dystonia; Rizk, T.M.G., Ed.; IntechOpen: London, UK, 2018.
21. Marsden, C.D. The problem of adult-onset idiopathic torsion dystonia and other isolated dyskinesias in adult life (including blepharospasm, oromandibular dystonia, dystonic writer’s cramp, and torticollis, or axial dystonia). Adv. Neurol. 1976, 14, 259–276.Yoshida, K. Botulinum neurotoxin therapy for lingual dystonia using an individualized injection method based on clinical features. Toxins 2019, 11, 51.
22. Yoshida, K. Development and validation of a disease-specific oromandibular dystonia rating scale (OMDRS). Front. Neurol. 2020, 11, 583177; doi: 10.3389/fneur.2020.583177Albanese, A.; Bhatia, K.; Bressman, S.B.; Delong, M.R.; Fahn, S.; Fung, V.S.; Hallett, M.; Jankovic, J.; Jinnah, H.A.; Klein, C.; et al. Phenomenology and classification of dystonia: A consensus up date. Mov. Disord. 2013, 28, 863–873.
23. Yoshida, K. Behandlungsstrategien bei oromandibulärer Dystonie. Fortschr. Neurol. Psychiatr. 2021, 89, 1562–572. doi: 10.1055/a-1375-0669.Oppenheim, H. Über eine eigenartige Krampfkrankheit des kindlichen und jugendlichen Alters (Dysbasia lordotica progressiva, Dystonia musculorum deformans). Neurol. Cent. 1911, 30, 1090–1107.
24. Yoshida, K.; Kaji, R.; Kubori, T. Kohara, N.; Iizuka, T.; Kimura, J. Muscle afferent block for the treatment of oromandibular dystonia. Mov. Disord. 1998; 13: 699–705. doi: 10.1002/mds.870130416.Romberg, M.H. Krampf im Muskelgebiete der Pars minor Quinti. Masticatorischer Gesichtskrampf. Trismus. In Lehrbuch der Nervenkaranheiten des Menschen; Alexander Duncker: Berlin, Germany, 1846; pp. 308–316.
25. Bakke, M. ; Dalager, T. ; Møller, E. What clinical strategies are applied for botulinum toxin injection in the oromandibular region? In Botulinum Toxin therapy manual for dystonia and spasticity. Editors Rosales, R.L.; Dressler, D. 2016; pp. 79-95, IntechOpen. https://doi.org/10.5772/64271Marsden, C.D. The problem of adult-onset idiopathic torsion dystonia and other isolated dyskinesias in adult life (including blepharospasm, oromandibular dystonia, dystonic writer’s cramp, and torticollis, or axial dystonia). Adv. Neurol. 1976, 14, 259–276.
26. Comella, C.L. Systematic review of botulinum toxin treatment for oromandibular dystonia. Toxicon 2018, 147, 96–99. [CrossRef]Yoshida, K. Development and validation of a disease-specific oromandibular dystonia rating scale (OMDRS). Front. Neurol. 2020, 11, 583177.
27. Slaim, L.; Cohen, M.; Klap, P.; Vidailhet, M.; Perrin, A.; Brasnu, D.; Ayache, D.; Mailly, M. Oromandibular dystonia: demographics and clinical data from 240 Patients. J. Mov. Disord. 2018, 11, 78–81. [CrossRef]Yoshida, K. Behandlungsstrategien bei oromandibulärer Dystonie. Fortschr. Neurol. Psychiatr. 2021, 89, 1562–1572.
28. Dadgardoust, P.D.; Rosales, R.L.; Asuncion, R.M.; Dressler, D. Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: A meta-analysis. J. Neural Transm. 2019, 126, 141–148. [CrossRef]Yoshida, K.; Kaji, R.; Kubori, T.; Kohara, N.; Iizuka, T.; Kimura, J. Muscle afferent block for the treatment of oromandibular dystonia. Mov. Disord. 1998, 13, 699–705.
29. Yoshida, K. Oromandibular dystonia screening questionnaire for differential diagnosis. Clin. Oral Investing. 2019, 23, 405–411; doi: 10.1007/s00784-018-2449-3.Bakke, M.; Dalager, T.; Møller, E. What clinical strategies are applied for botulinum toxin injection in the oromandibular region? In Botulinum Toxon Therapy Manual for Dystonia and Spasticity; Rosales, R.L., Dressler, D., Eds.; IntechOpen: London, UK, 2016; pp. 79–95.
30. Scorr, L.M.; Factor, S.A.; Parra, S.P.; Kaye, R.; Paniello, R.C.; Norris, S.A.; Perlmutter, J.S.; Bäumer, T.; Usnich, T.; Berman, B.D. et al. Oromandibular dystonia: A clinical examination of 2,020 cases. Front. Neurol. 2021, 12, 700714. doi: 10.3389/fneur.2021.700714. eCollection 2021.Comella, C.L. Systematic review of botulinum toxin treatment for oromandibular dystonia. Toxicon 2018, 147, 96–99.
31. Yoshida, K. Prevalence and incidence of oromandibular dystonia: an oral and maxillofacial surgery service-based study. Clin. Oral Investig. 2021, 25, 5755–5764, doi:10.1007/s00784-021-03878-9.Slaim, L.; Cohen, M.; Klap, P.; Vidailhet, M.; Perrin, A.; Brasnu, D.; Ayache, D.; Mailly, M. Oromandibular dystonia: Demographics and clinical data from 240 Patients. J. Mov. Disord. 2018, 11, 78–81.
32. Yoshida, K. Botulinum neurotoxin injection for the treatment of recurrent temporomandibular joint dislocation with and without neurogenic muscular hyperactivity. Toxins 2018, 10, 174; doi: 10.3390/toxins10050174.Dadgardoust, P.D.; Rosales, R.L.; Asuncion, R.M.; Dressler, D. Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: A meta-analysis. J. Neural Transm. 2019, 126, 141–148.
33. Defazio, G.; Albanese, A.; Pellicciari, R; Scaglione, C.L.; Esposito, M.; Morgante, F.; Abbruzzese, G.; Bentivoglio, A.R.; Bono, F. et al. Expert recommendations for diagnosing cervical, oromandibular, and limb dystonia. Neurol. Sci. 2019, 40, 89-95. doi: 10.1007/s10072-018-3586-9.Yoshida, K. Oromandibular dystonia screening questionnaire for differential diagnosis. Clin. Oral Investig. 2019, 23, 405–411.
34. Yoshida, K. Involuntary movements of the stomatognathic region. https://sites.google.com/site/oromandibulardystoniaenglish. Accessed 1 March 2022.Scorr, L.M.; Factor, S.A.; Parra, S.P.; Kaye, R.; Paniello, R.C.; Norris, S.A.; Perlmutter, J.S.; Bäumer, T.; Usnich, T.; Berman, B.D.; et al. Oromandibular dystonia: A clinical examination of 2,020 cases. Front. Neurol. 2021, 12, 700714.
35. Frucht, S.J. Embouchure dystonia--Portrait of a task-specific cranial dystonia. Mov. Disord. 2009, 24, 1752-1762. doi: 10.1002/mds.22550.Yoshida, K. Prevalence and incidence of oromandibular dystonia: An oral and maxillofacial surgery service-based study. Clin. Oral Investig. 2021, 25, 5755–5764.
36. Saraf, U.; Chandarana, M.; Divya, K.P.; Krishnan, S. Oromandibular dystonia – A systematic review. Ann. Indian Acad. Neurol. 2022, 25, 26-34. doi: 10.4103/aian.aian_242_21Yoshida, K. Botulinum neurotoxin injection for the treatment of recurrent temporomandibular joint dislocation with and without neurogenic muscular hyperactivity. Toxins 2018, 10, 174.
37. Meige, H. Les convulsions de la face, une forme clinique de convulsion faciale bilatérale et médiane. Revue Neurol. 1910, 20, 437–443.Defazio, G.; Albanese, A.; Pellicciari, R.; Scaglione, C.L.; Esposito, M.; Morgante, F.; Abbruzzese, G.; Bentivoglio, A.R.; Bono, F.; Moja, M.C.; et al. Expert recommendations for diagnosing cervical, oromandibular, and limb dystonia. Neurol. Sci. 2019, 40, 89–95.
38. Tolosa, E.S.; Klawans,K.H. Meige’s Disease: A clinical form of facial convulsion, bilateral and medial. Arch. Neurol. 1979, 36, 635–637. [CrossRef] [PubMed]Yoshida, K. Involuntary Movements of the Stomatognathic Region. Available online: https://sites.google.com/site/oromandibulardystoniaenglish (accessed on 1 March 2022).
39. Steeves, T.D.; Day, L.; Dykeman, J.; Jette, N.; Pringsheim, T. The prevalence of primary dystonia: a systematic review and meta-analysis. Mov. Disord, 2012, 27, 1789–1796. https://doi.org/10.1002/mds.25244Frucht, S.J. Embouchure dystonia—Portrait of a task-specific cranial dystonia. Mov. Disord. 2009, 24, 1752–1762.
40. Nutt, J.G; Muenter, M.D.; Aronson, A.; Kurland, L.T.; Melton 3rd, L.J. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov. Disord. 1988, 3, 188–194. https://doi.org/10.1002/mds.870030302Saraf, U.; Chandarana, M.; Divya, K.P.; Krishnan, S. Oromandibular dystonia—A systematic review. Ann. Indian Acad. Neurol. 2022, 25, 26–34.
41. Duffey, P.O.; Butler, A.G.; Hawthorne, M.R.; Barnes, M.P. The epidemiology of the primary dystonias in the north of England. Ad. Neurol. 1998, 78, 121–125.Meige, H. Les convulsions de la face, une forme clinique de convulsion faciale bilatérale et médiane. Revue Neurol. 1910, 20, 437–443.
42. Le, K-D.; Nilsen, B.; Dietrichs, E. Prevalence of primary focal and segmental dystonia in Oslo. Neurology 2003, 61, 1294–1296. https://doi.org/10.1212/01.wnl.0000090463.05980.59Tolosa, E.S.; Klawans, K.H. Meige’s Disease: A clinical form of facial convulsion, bilateral and medial. Arch. Neurol. 1979, 36, 635–637.
43. Castelon Konkiewitz, E.; Trender-Gerhard, I.; Kamm, C.; Warner, T.; Ben-Shlomo, Y.; Gasser, T.; Conrad, B.; Ceballos-Baumann, A.O. Service-based survey of dystonia in Munich. Neuroepidemiology 2002, 21, 202–206. https://doi.org/10.1159/000059525Steeves, T.D.; Day, L.; Dykeman, J.; Jette, N.; Pringsheim, T. The prevalence of primary dystonia: A systematic review and meta-analysis. Mov. Disord. 2012, 27, 1789–1796.
44. Matsumoto, S.; Nishimura, M.; Shibasaki, H.; Kaji, R. Epidemiology of primary dystonias in Japan: comparison with Western countries. Mov. Disord. 2003, 18, 1196–1198. https://doi.org/10.1002/mds.10480Nutt, J.G.; Muenter, M.D.; Aronson, A.; Kurland, L.T.; Melton, L.J. 3rd. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov. Disord. 1988, 3, 188–194.
45. Pekmezovic, T.; Ivanovic, N.; Svetel, M.; Nalić, D.; Smiljković, T.; Raicević, R.; Kostić, V.S. Prevalence of primary late-onset focal dystonia in the Belgrade population. Mov. Disord. 2003, 18, 1389–1392. https://doi.org/10.1002/mds.10615Duffey, P.O.; Butler, A.G.; Hawthorne, M.R.; Barnes, M.P. The epidemiology of the primary dystonias in the north of England. Ad. Neurol. 1998, 78, 121–125.
46. Asgeirsson, H.; Jakobsson, F.; Hjaltason, H.; Jonsdottir, H.; Sveinbjornsdottir, S. Prevalence study of primary dystonia in Iceland. Mov. Disord. 2006, 21, 293–298. https://doi.org/10.1002/mds.20674Le, K.-D.; Nilsen, B.; Dietrichs, E. Prevalence of primary focal and segmental dystonia in Oslo. Neurology 2003, 61, 1294–1296.
47. Joensen, P. High prevalence of primary focal dystonia in the Faroe Islands. Acta Neurol. Scand. 2016, 133, 55–60. https://doi.org/10.1111/ane.12438Castelon Konkiewitz, E.; Trender-Gerhard, I.; Kamm, C.; Warner, T.; Ben-Shlomo, Y.; Gasser, T.; Conrad, B.; Ceballos-Baumann, A.O. Service-based survey of dystonia in Munich. Neuroepidemiology 2002, 21, 202–206.
48. Williams, L.; McGovern, E.; Kimmich, O.; Molloy, A.; Beiser, I.; Butler, J.S.; Molloy, F.; Logan, P.; Healy, D.G.; T Lynch, T. Epidemiological, clinical and genetic aspects of adult onset isolated focal dystonia in Ireland. Eur. J. Neurol. 2017, 24, 73–81. https://doi.org/10.1111/ene.13133Matsumoto, S.; Nishimura, M.; Shibasaki, H.; Kaji, R. Epidemiology of primary dystonias in Japan: Comparison with Western countries. Mov. Disord. 2003, 18, 1196–1198.
49. Yoshida, K. Multilingual website and cyberconsultations for oromandibular dystonia. Neurol. Int. 2018, 10, 7536. doi: 10.4081/ni.2018.7536.Pekmezovic, T.; Ivanovic, N.; Svetel, M.; Nalić, D.; Smiljković, T.; Raicević, R.; Kostić, V.S. Prevalence of primary late-onset focal dystonia in the Belgrade population. Mov. Disord. 2003, 18, 1389–1392.
50. Yoshida, K. Computer-aided design/computer-assisted manufacture-derived needle guide for injection of botulinum toxin into the lateral pterygoid muscle in patients with oromandibular dystonia. J. Oral facial Pain Headache 2018, 32, e13–e21. doi: 10.11607/ofph.1955.Asgeirsson, H.; Jakobsson, F.; Hjaltason, H.; Jonsdottir, H.; Sveinbjornsdottir, S. Prevalence study of primary dystonia in Iceland. Mov. Disord. 2006, 21, 293–298.
51. Scorr, L.M.; Silver, M.R.; Hanfelt, J.; Sperin, E.; Freeman, A.; Jinnah, H.A. Factor, S.A. Pilot single-blind trial of AbobotulinumtoxinA in oromandibular dystonia. Neurotherapeutics 2018, 15, 452–458. doi: 10.1007/s13311-018-0620-9Joensen, P. High prevalence of primary focal dystonia in the Faroe Islands. Acta Neurol. Scand. 2016, 133, 55–60.
52. Skármeta, N.P.; Espinoza-Mellado, P.; Chana, P. Orofacial dystonia and other oromandibular movement disorders. In Dystonia, Editor, Rizk, T.M.G. IntecOpen, 2018; doi: 10.5772/intechopen.78607Williams, L.; McGovern, E.; Kimmich, O.; Molloy, A.; Beiser, I.; Butler, J.S.; Molloy, F.; Logan, P.; Healy, D.G.; Lynch, T.T. Epidemiological, clinical and genetic aspects of adult onset isolated focal dystonia in Ireland. Eur. J. Neurol. 2017, 24, 73–81.
53. Yoshida, K. Botulinum neurotoxin therapy for lingual dystonia using an individualized injection method based on clinical features. Toxins 2019, 11, 51. doi: 10.3390/toxins11010051.Yoshida, K. Multilingual website and cyberconsultations for oromandibular dystonia. Neurol. Int. 2018, 10, 7536.
54. Singer, C.; Papapetropoulos, S. A comparison of jaw-closing and jaw-opening idiopathic oromandibular dystonia. Parkinsonism Relat. Disord. 2006, 12, 115–118. doi: 10.1016/j.parkreldis.2005.07.007Van den Bergh, P.; Francart, J.; Mourin, S.; Kollmann, P.; Laterre, E.C. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve 1995, 18, 720–729.
55. Rosales, R.L.; Ng, A.R.; Santos, M.M.D-D.; Fernandez, H.H. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part II): an open-label experience with botulinum toxin-A (Dysport®) injections for oromandibular, lingual, and truncal-axial dystonias. Int. J. Neurosci. 2011, 121 Suppl 1, 44–56.doi: 10.3109/00207454.2011.558260.Bhattacharyya, N.; Tarsy, D. Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia. Arch. Otolaryngol. Head Neck Surg. 2001, 127, 389–392.
56. Teive, H.A.; Kluppel, L.E.; Munhoz, R.P.; Becker, N.; Muller, P.R.; Werneck, L.C. Jaw-opening oromandibular dystonia secondary to Wilson’s disease treated with botulinum toxin type A. Arq. Neuropsiquiatr. 2012, 70, 407–409. doi: 10.1590/S0004-282X2012000600 005Singer, C.; Papapetropoulos, S. A comparison of jaw-closing and jaw-opening idiopathic oromandibular dystonia. Parkinsonism Relat. Disord. 2006, 12, 115–118.
57. Jost, W. Pictorial Atlas of Botulinum Toxin Injection: Dosage, Localization, Application. 2nd ed.; Quintessence, Berlin, Germany, 2013.Rosales, R.L.; Ng, A.R.; Santos, M.M.D.-D.; Fernandez, H.H. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part II): An open-label experience with botulinum toxin-A (Dysport®) injections for oromandibular, lingual, and truncal-axial dystonias. Int. J. Neurosci. 2011, 121 (Suppl. S1), 44–56.
58. Moscovich, M.; Chen, Z.P.; Rodriguez, R. Successful treatment of open jaw and jaw deviation dystonia with botulinum toxin using a simple intraoral approach. J. Clin. Neurosci. 2015, 22, 594–596. doi: 10.1016/j.jocn.2014.08.027Teive, H.A.; Kluppel, L.E.; Munhoz, R.P.; Becker, N.; Muller, P.R.; Werneck, L.C. Jaw-opening oromandibular dystonia secondary to Wilson’s disease treated with botulinum toxin type A. Arq. Neuropsiquiatr. 2012, 70, 407–409.
59. Teemul, T.A.; Patel, R.; Kanatas, A.; Carter, L.M. Management of oromandibular dystonia with botulinum A toxin: a series of cases. Br. J. Oral Maxillofac. Surg. 2016, 54, 1080–1084. doi: 10.1016/j.bjoms.2016.06.028Jost, W. Pictorial Atlas of Botulinum Toxin Injection: Dosage, Localization, Application, 2nd ed.; Quintessence: Berlin, Germany, 2013.
60. Page, A.D.; Siegel, L.; Jog, M. Self-Rated communication-related quality of life of individuals with oromandibular dystonia receiving botulinum toxin injections. Am. J. Speech Lang. Pathol. 2017, 26, 674–681. [CrossRef] [PubMed]Moscovich, M.; Chen, Z.P.; Rodriguez, R. Successful treatment of open jaw and jaw deviation dystonia with botulinum toxin using a simple intraoral approach. J. Clin. Neurosci. 2015, 22, 594–596.
61. Bakke, M. ; Henriksen, T.; Biernat, H.B.; Dalager, T. ; Møller, E. Interdisciplinary recognizing and managing of drug-induced tardive oromandibular dystonia: two case reports. Clin. Case Rep. 2018, 6, 2150–2155.doi: 10.1002/ccr3.1548Teemul, T.A.; Patel, R.; Kanatas, A.; Carter, L.M. Management of oromandibular dystonia with botulinum A toxin: A series of cases. Br. J. Oral Maxillofac. Surg. 2016, 54, 1080–1084.
62. Bakke, M.; Baram, S.; Dalager, T.; Biernat, H.B.; Møller, E. Oromandibular dystonia, mental distress and oro-facial dysfunction— A follow-up 8–10 years after start of treatment with botulinum toxin. Oral Rehabil. 2019, 46, 441–449. [CrossRef]Page, A.D.; Siegel, L.; Jog, M. Self-Rated communication-related quality of life of individuals with oromandibular dystonia receiving botulinum toxin injections. Am. J. Speech Lang. Pathol. 2017, 26, 674–681.
63. Dressler, D.; Altavista, M.C.; Altenmueller, E.; Bhidayasiri, R.; Bohlega, S.; Chana, P.; Chung, T.M.; Colosimo, C.; Fheodoroff, K.; Garcia-Ruiz, PJ. et al. Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. J. Neural. Transm. (Vienna). 2021, 128, 321–335. doi: 10.1007/s00702-021-02312-4.Epub 2021 Feb 26.Bakke, M.; Henriksen, T.; Biernat, H.B.; Dalager, T.; Møller, E. Interdisciplinary recognizing and managing of drug-induced tardive oromandibular dystonia: Two case reports. Clin. Case Rep. 2018, 6, 2150–2155.
64. Yoshida, K.; Kaji, R.; Shibasaki, H.; Iizuka , T. Factors influencing the therapeutic effect of muscle afferent block for oromandibular dystonia and dyskinesia: implications for their distinct pathophysiology. Int. J. Oral Maxillofac. Surg. 2002; 31: 499–505. doi: 10.1054/ijom.2002.0291.Bakke, M.; Baram, S.; Dalager, T.; Biernat, H.B.; Møller, E. Oromandibular dystonia, mental distress and oro-facial dysfunction— A follow-up 8–10 years after start of treatment with botulinum toxin. J. Oral Rehabil. 2019, 46, 441–449.
65. Yoshida, K.; Kaji, R.; Takagi, A.; Iizuka, T. Customized EMG needle insertion guide for the muscle afferent block of jaw-deviation and jaw-opening dystonias. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 1999, 88, 664–669. doi: 10.1016/s1079-2104(99)70006-5.Dressler, D.; Altavista, M.C.; Altenmueller, E.; Bhidayasiri, R.; Bohlega, S.; Chana, P.; Chung, T.M.; Colosimo, C.; Fheodoroff, K.; Garcia-Ruiz, P.J.; et al. Consensus guidelines for botulinum toxin therapy: General algorithms and dosing tables for dystonia and spasticity. J. Neural. Transm. 2021, 128, 321–335.
66. Yoshida, K. Sensory trick splint as a multimodal therapy for oromandibular dystonia. J. Prosthodont. Res. 2018, 62, 239–244; doi: 10.1016/j.jpor.2017.09.004.Yoshida, K.; Kaji, R.; Shibasaki, H.; Iizuka, T. Factors influencing the therapeutic effect of muscle afferent block for oromandibular dystonia and dyskinesia: Implications for their distinct pathophysiology. Int. J. Oral Maxillofac. Surg. 2002, 31, 499–505.
67. De Meyer, M.; Vereecke, L.; Bottenberg, P.; Jacquet, W.; Sims, A.B.; Santens, P. Oral appliances in the treatment of oromandibular dystonia: a systematic review. Acta Neurol. Belg. 2020, 120, 831–836. doi: 10.1007/s13760-020-01404-4.Yoshida, K.; Kaji, R.; Takagi, A.; Iizuka, T. Customized EMG needle insertion guide for the muscle afferent block of jaw-deviation and jaw-opening dystonias. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 1999, 88, 664–669.
68. Yoshida, K. Coronoidotomy as treatment for trismus due to jaw-closing oromandibular dystonia. Mov. Disord. 2006, 21, 1028–1031; doi: 10.1002/mds.20859.Yoshida, K. Sensory trick splint as a multimodal therapy for oromandibular dystonia. J. Prosthodont. Res. 2018, 62, 239–244.
69. Yoshida, K. Surgical intervention for oromandibular dystonia-related limited mouth opening: long-term follow-up. J. Cranio-Maxillofac. Surg. 2017, 45, 56–62; doi: 10.1016/j.jcms.2016.10.009.De Meyer, M.; Vereecke, L.; Bottenberg, P.; Jacquet, W.; Sims, A.B.; Santens, P. Oral appliances in the treatment of oromandibular dystonia: A systematic review. Acta Neurol. Belg. 2020, 120, 831–836.
70. Yoshida, K. Mouth opening retaining appliance after coronoidotomy for the treatment of trismus: effects on pain during postoperative training and maximal extent of mouth opening. Clin. Surg. 2020, 5, 2737.Yoshida, K. Coronoidotomy as treatment for trismus due to jaw-closing oromandibular dystonia. Mov. Disord. 2006, 21, 1028–1031.
71. Spiegel, L.L.; Ostrem, J.L.; Bledsoe, I.O. FDA approvals and consensus guidelines for botulinum toxins in the treatment of dystonia. Toxins 2020, 12, 332.doi: 10.3390/toxins12050332.Yoshida, K. Surgical intervention for oromandibular dystonia-related limited mouth opening: Long-term follow-up. J. Cranio-Maxillofac. Surg. 2017, 45, 56–62.
72. Jankovic, J. Botulinum toxin: State of the art. Mov. Disord. 2017, 32, 1131–1138. [CrossRef]Yoshida, K. Mouth opening retaining appliance after coronoidotomy for the treatment of trismus: Effects on pain during postoperative training and maximal extent of mouth opening. Clin. Surg. 2020, 5, 2737.
73. Albrecht, P.; Jansen, A.; Lee, J.I.; Moll, M.; Ringelstein, M.; Rosenthal, D.; Bigalke, H.; Aktas, O.; Hartung, H.P.; Hefter, H. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology 2019, 92, E48–E54. [CrossRef]Spiegel, L.L.; Ostrem, J.L.; Bledsoe, I.O. FDA approvals and consensus guidelines for botulinum toxins in the treatment of dystonia. Toxins 2020, 12, 332.
74. Jankovic, J.; Schwartz, K. Response and immunoresistance to botulinum toxin injections. Neurology 1995, 45, 1743–1746. [CrossRef]Jankovic, J. Botulinum toxin: State of the art. Mov. Disord. 2017, 32, 1131–1138.
75. Brin, M.F.; Comella, C.L.; Jankovic, J.; Lai, F.; Naumann, M.; Ahmed, F.; Brashear, A.; Chehrenama, M.; Erjanti, H.; Evatt, M.; et al. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov. Disord. 2008, 23, 1353–1360. [CrossRef]Albrecht, P.; Jansen, A.; Lee, J.I.; Moll, M.; Ringelstein, M.; Rosenthal, D.; Bigalke, H.; Aktas, O.; Hartung, H.P.; Hefter, H. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology 2019, 92, E48–E54.
76. Naumann, M.; Boo, L.M.; Ackerman, A.H.; Gallagher, C.J. Immunogenicity of botulinum toxins. J. Neural Transm. 2013, 120,275–290. [CrossRef]Jankovic, J.; Schwartz, K. Response and immunoresistance to botulinum toxin injections. Neurology 1995, 45, 1743–1746.
77. Yoshida, K. Effects of botulinum toxin type A on pain among trigeminal neuralgia, myofascial temporomandibular disorders, and oromandibular dystonia. Toxins 2021, 13, 605, https://doi.org/10.3390/toxins13090605Brin, M.F.; Comella, C.L.; Jankovic, J.; Lai, F.; Naumann, M.; Ahmed, F.; Brashear, A.; Chehrenama, M.; Erjanti, H.; Evatt, M.; et al. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov. Disord. 2008, 23, 1353–1360.
78.  Boyle,H.; McGwin Jr, G.; Flanagan, C.E.; Vicinanzo, M.G.; Long, J.A. High versus low concentration botulinum toxin A for benign essential blepharospasm: does dilution make a difference? Ophthalmic Plast. Reconstr. Surg. 2009, 25, 81–84. doi: 10.1097/IOP.0b013e31819946c4.Naumann, M.; Boo, L.M.; Ackerman, A.H.; Gallagher, C.J. Immunogenicity of botulinum toxins. J. Neural Transm. 2013, 120, 275–290.
79. Jost, W.H. How Do I treat cervical dystonia with botulinum toxin by using ultrasound? Mov. Disord. Clin. Pract. 2017, 4, 647. doi: 10.1002/mdc3.12468.Yoshida, K. Effects of botulinum toxin type A on pain among trigeminal neuralgia, myofascial temporomandibular disorders, and oromandibular dystonia. Toxins 2021, 13, 605.
80. Fietzek, U.M.; Nene, D.; Schramm, A.; Appel-Cresswell, S.; Košutzká, Z.; Walter, U.; Wissel, J.; Berweck, S.; Chouinard, S.; Bäumer, T. The role of ultrasound for the personalized botulinum toxin treatment of cervical dystonia. Toxins 2021, 13, 365.doi: 10.3390/toxins13050365.Boyle, M.H.; McGwin Jr, G.; Flanagan, C.E.; Vicinanzo, M.G.; Long, J.A. High versus low concentration botulinum toxin A for benign essential blepharospasm: Does dilution make a difference? Ophthalmic Plast. Reconstr. Surg. 2009, 25, 81–84.
81. Yoshida, K. Is botulinum toxin therapy effective for bruxism? Anti-Ageng Med. 2017, 13, 394–398.Jost, W.H. How Do I treat cervical dystonia with botulinum toxin by using ultrasound? Mov. Disord. Clin. Pract. 2017, 4, 647.
82. Yoshida, K. Clinical application of botulinum neurotoxin for diseases in the stomatognathic system. J. Jpn. Dent. Soc. Anesthesiol. 2020, 48, 33‒40.Fietzek, U.M.; Nene, D.; Schramm, A.; Appel-Cresswell, S.; Košutzká, Z.; Walter, U.; Wissel, J.; Berweck, S.; Chouinard, S.; Bäumer, T. The role of ultrasound for the personalized botulinum toxin treatment of cervical dystonia. Toxins 2021, 13, 365.
83. Yoshida, K. How do I inject botulinum toxin into the lateral and medial pterygoid muscles? Mov. Disord. Clin. Pract. 2016, 4, 285. doi: 10.1002/mdc3.12460.Yoshida, K. Is botulinum toxin therapy effective for bruxism? Anti-Aging Med. 2017, 13, 394–398.
84. Yoshida, K. An electromyographic study on the superior head of the lateral pterygoid muscle during mastication from the standpoint of condylar movement. J. Jpn. Prosthodont. Soc. 1992, 36, 110–120. [CrossRef]Yoshida, K. Clinical application of botulinum neurotoxin for diseases in the stomatognathic system. J. Jpn. Dent. Soc. Anesthesiol. 2020, 48, 33–40.
85. Yoshida, K. Masticatory muscle responses associated with unloading of biting force during food crushing. J. Oral Rehabil. 1998, 25, 830–837. [CrossRef] [PubMed]Yoshida, K. How do I inject botulinum toxin into the lateral and medial pterygoid muscles? Mov. Disord. Clin. Pract. 2016, 4, 285.
86. Yoshida, K. Clinical and phenomenological characteristics of patients with task-specific lingual dystonia: Possible association with occupation. Front. Neurol. 2017, 8, 649. [CrossRef] [PubMed]Yoshida, K. An electromyographic study on the superior head of the lateral pterygoid muscle during mastication from the standpoint of condylar movement. J. Jpn. Prosthodont. Soc. 1992, 36, 110–120.
87. Berkovitz, B.K.B. Tongue. In Gray’s Anatomy, 41st ed.; Standring, S., Ed.; Elsevier: Amsterdam,The Netherlands, 2016; pp. 511–517.Yoshida, K. Masticatory muscle responses associated with unloading of biting force during food crushing. J. Oral Rehabil. 1998, 25, 830–837.
88. Blitzer, A.; Brin, M.F.; Fahn, S. Botulinum toxin injections for lingual dystonia. Laryngoscope 1991, 101, 799. [CrossRef] [PubMed]Yoshida, K. Clinical and phenomelogical characteristics of patients with task-specific lingual dystonia: Possible association with occupation. Front. Neurol. 2017, 8, 649.
89. Schneider, S.A.; Aggarwal, A.; Bhatt, M.; Dupont, E.; Tisch, S.; Limousin, P.; Lee, P.; Quinn, N.; Bhatia, K.P. Severe tongue protrusion dystonia Clinical syndromes and possible treatment. Neurology 2006, 67, 940–943. [CrossRef]Berkovitz, B.K.B. Tongue. In Gray’s Anatomy, 41st ed.; Standring, S., Ed.; Elsevier: Amsterdam, The Netherlands, 2016; pp. 511–517.
90. Esper, C.D.; Freeman, A.; Factor, S.A. Lingual protrusion dystonia: Frequency, etiology and botulinum toxin therapy. Park. Relat. Disord. 2010, 16, 438–441. [CrossRef] [PubMed]Blitzer, A.; Brin, M.F.; Fahn, S. Botulinum toxin injections for lingual dystonia. Laryngoscope 1991, 101, 799.
91. Nastasi, L.; Mostile, G.; Nicoletti, A.; Zappia, M.; Reggio, E.; Catania, S. Effect of botulinum toxin treatment on quality of life in patients with isolated lingual dystonia and oromandibular dystonia affecting the tongue. J. Neurol. 2016, 263, 1702–1708. [CrossRef] [PubMed]Schneider, S.A.; Aggarwal, A.; Bhatt, M.; Dupont, E.; Tisch, S.; Limousin, P.; Lee, P.; Quinn, N.; Bhatia, K.P. Severe tongue protrusion dystonia Clinical syndromes and possible treatment. Neurology 2006, 67, 940–943.
92. Charles, P.D.; Davis, T.L.; Shannon, K.M.; Hook, M.A.; Warner, J.S. Tongue protrusion dystonia: Treatment with botulinum toxin. South Med. J. 1997, 90, 522–525. [CrossRef] [PubMed]Esper, C.D.; Freeman, A.; Factor, S.A. Lingual protrusion dystonia: Frequency, etiology and botulinum toxin therapy. Park. Relat. Disord. 2010, 16, 438–441.
93. Ondo,W. Lingual dystonia following electrical injury. Mov. Disord. 1997, 12, 253. [CrossRef] [PubMed]Nastasi, L.; Mostile, G.; Nicoletti, A.; Zappia, M.; Reggio, E.; Catania, S. Effect of botulinum toxin treatment on quality of life in patients with isolated lingual dystonia and oromandibular dystonia affecting the tongue. J. Neurol. 2016, 263, 1702–1708.
94. Hennings, J.M.H.; Krause, E.; Bötzel, K.; Wetter, T.C. Successful treatment of tardive lingual dystonia with botulinum toxin: Case report and review of the literature. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32, 1167–1171. [CrossRef] [PubMed]Charles, P.D.; Davis, T.L.; Shannon, K.M.; Hook, M.A.; Warner, J.S. Tongue protrusion dystonia: Treatment with botulinum toxin. South Med. J. 1997, 90, 522–525.
95. Kasravi, N.; Jog, M.S. Botulinum toxin in the treatment of lingual movement disorders. Mov. Disord. 2009, 24, 2199–2202. [CrossRef] [PubMed]Ondo, W. Lingual dystonia following electrical injury. Mov. Disord. 1997, 12, 253.
96. Yoshida, K. Clinical characteristics of functional movement disorders in the stomatognathic system. Front. Neurol. 2020, 11: 23, doi: 10.3389/fneur.2020.00123.Hennings, J.M.H.; Krause, E.; Bötzel, K.; Wetter, T.C. Successful treatment of tardive lingual dystonia with botulinum toxin: Case report and review of the literature. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32, 1167–1171.
97. Sankhla, C.; Lai, E.C.; Jankovic, J. Peripherally induced oromandibular dystonia. J. Neurol. Neurosurg. Psychiatry 1998, 65, 722–728. doi: 10.1136/jnnp.65.5.722Kasravi, N.; Jog, M.S. Botulinum toxin in the treatment of lingual movement disorders. Mov. Disord. 2009, 24, 2199–2202.
98. Raphael, K.G.; Tadinada, A.; Bradshaw, J.M.; Janal, M.N.; Sirois, D.A.; Chan, K.C.; Lurie, A.G. Osteopenic consequences of botulinum toxin injections in the masticatory muscles: A pilot study. J. Oral Rehabil. 2014, 41, 555–563. doi: 10.1111/joor.12180.Yoshida, K. Clinical characteristics of functional movement disorders in the stomatognathic system. Front. Neurol. 2020, 11, 23.
99. Lee, H.J.; Kim, S.J.; Lee, K.J.; Yu, H.S.; Baik, H.S. Repeated injections of botulinum toxin into the masseter muscle induce bony changes in human adults: a longitudinal study. Korean J. Orthod. 2017, 47, 222–228. doi: 10.4041/kjod.2017.47.4.222.Shaikh, A.G.; Riley, D.E.; Gunzler, S.A. Teaching video neuroimages: Essential palatal tremor: Is it a peripherally triggered central movement disorder? Neurology 2012, 79, e142.
100. Chang, C.S.; Bergeron, L.; Yu, C.C.; Chen, P.K.; Chen, Y.R. Mandible changes evaluated by computed tomography following Botulinum Toxin A injections in square-faced patients. Aesthetic Plast. Surg. 2011, 35, 452–455. doi: 10.1007/s00266-010-9624-5.Sankhla, C.; Lai, E.C.; Jankovic, J. Peripherally induced oromandibular dystonia. J. Neurol. Neurosurg. Psychiatry 1998, 65, 722–728.
101. Merz, R.I.; Deakin, J.; Hawthorne, M.R. Oromandibular dystonia questionnaire (OMDQ-25): a valid and reliable instrument for measuring health-related quality of life. Clin. Otolaryngol. 2010, 35, 390–396. doi: 10.1111/j.1749-4486.2010.02194.xRaphael, K.G.; Tadinada, A.; Bradshaw, J.M.; Janal, M.N.; Sirois, D.A.; Chan, K.C.; Lurie, A.G. Osteopenic consequences of botulinum toxin injections in the masticatory muscles: A pilot study. J. Oral Rehabil. 2014, 41, 555–563.
102. Simpson, D.M.; Blitzer, A.; Brashear, A.; Comella, C.; Dubinsky, R.; Hallett, M.; Jankovic, J.; Karp, B.; Ludlow, C.L.; Miyasaki, J.M. et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70, 1699–1706. [CrossRef]Lee, H.J.; Kim, S.J.; Lee, K.J.; Yu, H.S.; Baik, H.S. Repeated injections of botulinum toxin into the masseter muscle induce bony changes in human adults: A longitudinal study. Korean J. Orthod. 2017, 47, 222–228.
103. Simpson, D.M.; Hallett, M.; Ashman, E.J.; Comella, C.L.; Green, M.W.; Gronseth, G.S.; Armstrong, M.J.; Gloss, D.; Potrebic, S.; Jankovic, J. et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2016, 86, 1818–1826. [CrossRef]Chang, C.S.; Bergeron, L.; Yu, C.C.; Chen, P.K.; Chen, Y.R. Mandible changes evaluated by computed tomography following Botulinum Toxin A injections in square-faced patients. Aesthetic Plast. Surg. 2011, 35, 452–455.
104. Albanese, A.; Asmus, F.; Bhatia, K.P.; Elia, A.E.; Elibol, B.; Filippini, G.; Gasser, T.; Krauss, J.K.; Nardocci, N.; Newton, A.; Valls-Sole, J. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur, J. Neurol. 2011, 18, 5–18.Merz, R.I.; Deakin, J.; Hawthorne, M.R. Oromandibular dystonia questionnaire (OMDQ-25): A valid and reliable instrument for measuring health-related quality of life. Clin. Otolaryngol. 2010, 35, 390–396.
105. France, K.; Stoopler, E.T. The American Academy of Oral Medicine Clinical Practice Statement: Oromandibular dystonia. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2018, 125, 283–285. doi: 10.1016/j.oooo.2018.01.023.Simpson, D.M.; Blitzer, A.; Brashear, A.; Comella, C.; Dubinsky, R.; Hallett, M.; Jankovic, J.; Karp, B.; Ludlow, C.L.; Miyasaki, J.M.; et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70, 1699–1706.
106. Simpson, D.M.; Hallett, M.; Ashman, E.J.; Comella, C.L.; Green, M.W.; Gronseth, G.S.; Armstrong, M.J.; Gloss, D.; Potrebic, S.; Jankovic, J.; et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2016, 86, 1818–1826.
107. Albanese, A.; Asmus, F.; Bhatia, K.P.; Elia, A.E.; Elibol, B.; Filippini, G.; Gasser, T.; Krauss, J.K.; Nardocci, N.; Newton, A.; et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur. J. Neurol. 2011, 18, 5–18.
108. Cantarella, G.; Berlusconi, A.; Mele, V.; Cogiamanian, F.; Barbieri, S. Treatment of Frey’s syndrome with botulinum toxin type B. Otolaryngol. Head Neck Surg. 2010, 143, 214–218.
109. France, K.; Stoopler, E.T. The American Academy of Oral Medicine Clinical Practice Statement: Oromandibular dystonia. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2018, 125, 283–285.
110. Yoshida, K. Sphenopalatine ganglion block with botulinum neurotoxin for treating trigeminal neuralgia using CAD/CAM-derived injection guide. J. Oral Facial. Pain Headache 2020, 34, 135–140.
111. von Lindern, J.J. Type A botulinum toxin in the treatment of chronic facial pain associated with temporo-mandibular dysfunction. Acta Neurol. Belg. 2001, 101, 39–41.
112. Nixdorf, D.R.; Heo, G.; Major, P.W. Randomized controlled trial of botulinum toxin for chronic myogenous orofacial pain. Pain 2002, 99, 465–473.
113. Boutsen, F.; Cannito, M.P.; Taylor, M.; Bender, B. Botox treatment in adductor spasmodic dysphonia: A meta-analysis. J. Speech Lang. Hear. Res. 2002, 45, 469–481.